Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | ELANE | P08246 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 11/20 | 0.52 |
| ▸ | NPC1 | O15118 | 9/20 | 0.52 |
| ▸ | MAPT | P10636 | 8/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14693776 | 0.84 | MMP2 (0.56) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL220196 | 0.81 | MEN1 (0.62) | MEN1KMT2AELANERAB9ANPC1 | |
| SCHEMBL14693756 | 0.79 | MAOB (0.68) | RAB9ANPC1MAPTSMN1; SMN2LMNA | |
| SCHEMBL3137128 | 0.79 | RAB9A (0.82) | MEN1KMT2AELANERAB9ANPC1 | |
| SCHEMBL14707629 | 0.78 | MAOB (0.67) | MEN1KMT2AELANERAB9ANPC1 | |
| SCHEMBL4512191 | 0.77 | RAB9A (0.67) | MEN1KMT2AELANERAB9ANPC1 | |
| SCHEMBL14693911 | 0.77 | MAOB (0.65) | MAOB | |
| SCHEMBL14693918 | 0.77 | PBRM1 (0.58) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2491306 | 0.76 | MMP2 (0.72) | MEN1KMT2AELANERAB9ANPC1 | |
| SCHEMBL7921287 | 0.76 | RAB9A (0.82) | MEN1KMT2AELANERAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560008-B1 | Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same | KOREA INST SCI & TECH (KR) | 2016-11-30 | — | — | EP | disclosed |
| EP-2560008-B1 | Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same | KOREA INST SCI & TECH (KR) | 2016-11-30 | — | — | EP | disclosed |
| US-9469653-B2 | Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-10-18 | — | — | US | disclosed |
| US-9469653-B2 | Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-10-18 | — | — | US | disclosed |
| US-9469653-B2 | Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-10-18 | — | — | US | disclosed |
| US-20140142089-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE AND METHOD OF SCREENING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-05-22 | — | — | US | disclosed |
| US-20140142089-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE AND METHOD OF SCREENING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-05-22 | — | — | US | disclosed |
| US-20140142089-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE AND METHOD OF SCREENING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-05-22 | — | — | US | disclosed |
| US-20130046093-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE AND METHOD OF SCREENING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-02-21 | — | — | US | disclosed |
| US-20130046093-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE AND METHOD OF SCREENING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-02-21 | — | — | US | disclosed |
| US-20130046093-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE AND METHOD OF SCREENING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-02-21 | — | — | US | disclosed |
| EP-2560008-A2 | Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same | Korea Institute of Science and Technology (KR) | 2013-02-20 | — | — | EP | disclosed |
| EP-2560008-A2 | Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same | Korea Institute of Science and Technology (KR) | 2013-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142089-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE AND METHOD OF SCREENING THE SAME | PSEN2, PSEN1, GRN | MEN1 1416/4885KMT2A 4162/4885ELANE 719/4885 |
| US-20130046093-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE AND METHOD OF SCREENING THE SAME | PSEN2, PSEN1, GRN | MEN1 1416/4885KMT2A 4162/4885ELANE 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.